The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: severe cutaneous adverse reaction (Stevens Johnson, DRESS) following therapy with an immune checkpoint inhibitor
Parameters:
(1) percent of body surface area showing sloughing
(2) mucosal involvement (erythema, purpura, epidermal detachment, mucous membrane detachment)
(3) systemic findings (including abnormal laboratory tests of hepatitis, etc)
|
BSA Skin Sloughing
|
Mucosal Involvement
|
Systemic Findings
|
Grade
|
|
< 10%
|
present
|
absent
|
G3
|
|
>= 10%
|
present
|
NA
|
G4
|
|
NA
|
NA
|
present
|
G4
|
The diagnosis requires exclusion of other conditions that can explain the findings better.
